|
BRCA1/2 reversion mutations in pancreatobiliary cancer identified from patient biopsies. |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine; Gilead Sciences |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Travel, Accommodations, Expenses - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Honoraria - EMD Serono; Pfizer |
Research Funding - Foundation Medicine |